Dr. Jeremy P. Cetnar
Claim this profileOregon Health and Science University
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
23 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
2Lung Cancer
Stage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Jeremy P. Cetnar is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Sotorasib
for Non-Small Cell Lung Cancer
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
More about Jeremy P. Cetnar
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jeremy P. Cetnar has experience with
- Pembrolizumab
- Atezolizumab
- Ramucirumab
- NT-I7
- Tisotumab Vedotin
- Carboplatin
Breakdown of trials Jeremy P. Cetnar has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Recurrence
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeremy P. Cetnar specialize in?
Jeremy P. Cetnar focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jeremy P. Cetnar currently recruiting for clinical trials?
Yes, Jeremy P. Cetnar is currently recruiting for 6 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Jeremy P. Cetnar has studied deeply?
Yes, Jeremy P. Cetnar has studied treatments such as Pembrolizumab, Atezolizumab, Ramucirumab.
What is the best way to schedule an appointment with Jeremy P. Cetnar?
Apply for one of the trials that Jeremy P. Cetnar is conducting.
What is the office address of Jeremy P. Cetnar?
The office of Jeremy P. Cetnar is located at: Oregon Health and Science University, Portland, Oregon 97239-3098 United States. This is the address for their practice at the Oregon Health and Science University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.